Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Landscape of copy number variants in Spanish people with dementia.

NPJ genomic medicine·2026
Same author

Listening for Alzheimer's clues: machine learning analysis of multidomain speech features for cognitive impairment screening.

Frontiers in aging neuroscience·2026
Same author

Non-linear associations between sleep duration and plasma p-tau181 in the Framingham Heart Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease.

Science translational medicine·2026
Same author

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Nature communications·2026
Same author

Unveiling pathogens and contaminants: refining metagenomics for clinical diagnostics.

Frontiers in microbiology·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Maria Capdevila1, Raquel Puerta1, Laura Montrreal1

  • 1Ace Alzheimer Center Barcelona, Barcelona, Spain.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

血pTau217显示为阿尔茨海默氏症 (AD) 风险查工具的前景,在临床前阶段表现优于pTau181. 在临床广泛采用之前需要进一步验证.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物发现发现
  • 临床诊断 临床诊断 临床诊断

背景情况:

  • 对于阿尔茨海默病 (AD) 的疾病修饰药物的出现需要可靠的诊断工具.
  • 血生物标志物正在成为临床环境中AD风险评估的实际解决方案.

研究的目的:

  • 评估血pTau217作为在现实世界记忆诊所环境中对AD风险的查工具的疗效.
  • 为了比较血pTau217与血pTau181的性能,以及已知的诊断方法.

主要方法:

  • 分析了来自认知衰退患者的2353个配对脑脊液 (CSF) 和血样本.
  • 使用Lumipulse G1200平台测量pTau181和pTau217等离子体.
  • 统计分析包括ROC曲线,相关性和生存分析.

主要成果:

  • 血pTau217与CSF生物标志物有很强的相关性,并且具有很高的诊断准确性 (AUC=0.97).
  • 血pTau217在临床前AD阶段表现优于pTau181.
  • 血pTau217水平与MRI上与AD相关的大脑变化相关,并预测MCI转化为AD痴呆症.

结论:

  • 血pTau217是一种强大的生物标志物,用于查AD风险,特别是在临床前阶段.
  • 虽然有希望,但血生物标志物需要进一步验证,尚未成为独立的诊断试验.
  • 为了完善血生物标志物以最终取代CSF/PET诊断,继续进行研究至关重要.